von Willebrand factor – Factor VIII complex (VWF-FVIII)

The von Willebrand factor (VWF) – Factor VIII (FVIII) complex is a critical protein-protein interaction in the human circulatory system that regulates blood clotting. VWF serves as the essential carrier protein for FVIII, protecting it from rapid proteolytic degradation by activated protein C and preventing its premature clearance from the plasma (Lenting et al., 2007, Journal of Thrombosis and Haemostasis). This interaction increases the half-life of FVIII by approximately 20-fold, ensuring sufficient levels are available for the coagulation cascade. Defects in this interaction, such as those seen in von Willebrand disease Type 2N, lead to significantly reduced FVIII levels and clinical symptoms mimicking Hemophilia A (Lillicrap, 2013, Blood). In therapeutic development, this interaction is targeted to extend the half-life of FVIII replacement therapies, notably through the use of VWF fragments or Fc-fusion proteins that bypass the limitations of endogenous VWF binding. For example, efanesoctocog alfa utilizes a VWF D'D3 domain to decouple FVIII from endogenous VWF, thereby overcoming the half-life ceiling imposed by the carrier protein (Lissitchkov et al., 2023, NEJM). Understanding and modulating this complex is vital for managing bleeding disorders and improving the pharmacokinetic profiles of clotting factor concentrates.

Other names

VWF-FVIII interactionFactor VIII-von Willebrand factor complexVWF-FVIII bindingVWF-FVIII carrier protein interaction

Stabilization of Factor VIII in circulation, protection of Factor VIII from proteolytic degradation, and localization of Factor VIII to sites of vascular injury.